

# **Propranolol and Oxytocin versus Oxytocin Alone for Induction of Labor: A Randomized Controlled Trial**

## **Thesis**

Submitted for partial fulfillment of Master degree  
in *Obstetrics and Gynecology*

**By**

**Abd El-Rahman Mahmoud Abd El-Rahman**

M.B,B.Ch Al-Azhar University - 2010  
Resident of Obstetrics & Gynecology-Tahta General Hospital

**Under Supervision of**

**Prof. Magdy Mohamed Mahmoud Abd El-Gawad**

Professor of Obstetrics and Gynecology  
Faculty of Medicine - Ain-Shams University

**Dr. Reda Mokhtar Kamal**

Lecturer of Obstetrics and Gynecology  
Faculty of Medicine - Ain-Shams University



Faculty of Medicine  
Ain Shams University  
**2019**



## Acknowledgments

*First and foremost, I feel always indebted to **Allah**, the Most Beneficent and Merciful who gave me the strength to accomplish this work,*

*My deepest gratitude to my supervisor, **Prof. Magdy Mohamed Mahmoud Abd El-Gawad**, Professor of Obstetrics and Gynecology, Faculty of Medicine - Ain-Shams University,, for his valuable guidance and expert supervision, in addition to his great deal of support and encouragement. I really have the honor to complete this work under his supervision.*

*I would like to express my great thanks to **Dr. Reda Mokhtar Kamal**, Lecturer in Obstetrics and Gynecology, Faculty of Medicine - Ain-Shams University, for his meticulous supervision, and his patience in reviewing and correcting this work,*

*Special thanks to my **Patients** who accepted to help me in this study.*



*Abd El-Rahman Mahmoud*

Thata \* Sohag

March, 2019

## **List of Contents**

<i><b>Subject</b></i>	<i><b>Page No.</b></i>
<b>List of Abbreviations.....</b>	<b>i</b>
<b>List of Tables.....</b>	<b>ii</b>
<b>List of Figures .....</b>	<b>vii</b>
<b>Introduction .....</b>	<b>1</b>
<b>Aim of the Work.....</b>	<b>4</b>
<b>Review of Literature</b>	
Physiology of Labor .....	6
Induction of Labor.....	26
Pharmacology of Oxytocin and Propranolol.....	57
Propranolol and oxytocin for induction of labor .....	77
<b>Subjects and Methods .....</b>	<b>82</b>
<b>Results.....</b>	<b>99</b>
<b>Discussion .....</b>	<b>108</b>
<b>Summary .....</b>	<b>118</b>
<b>Conclusion.....</b>	<b>125</b>
<b>Recommendations .....</b>	<b>126</b>
<b>References .....</b>	<b>127</b>
<b>Arabic Summary .....</b>	<b>—</b>

---

## List of Abbreviations

<i>Abbr.</i>	<i>Full-term</i>
<b>ACTH</b>	: Adreno Corticotropin Hormone
<b>CAPs</b>	: Contraction Associated Proteins
<b>CNS</b>	: Central Nervous System
<b>CRH</b>	: Corticotrpin Releasing Hormone
<b>CS</b>	: Cesarean Section
<b>CTRH –BP</b>	: CorticoTropin Releasing Hormone –Binding Protine
<b>D5W</b>	: 5% Dextrose in Water
<b>DHEAS</b>	: DeHydroepiandrosterone sulfate
<b>FHR</b>	: Fetal Heart Rate
<b>FFN</b>	: Fetal Fibronectin
<b>GBS</b>	: Group B Streptococcus
<b>IL-1</b>	: Interleukin -1
<b>IOL</b>	: Induction Of Labor
<b>ISA</b>	: Intrinsic Sympathomimetics Activity
<b>MI</b> s	: Myocardial Infarction
<b>MMPs</b>	: Matrix Metaloproteases
<b>NICU</b>	: Neonatal Intensive Care Unit
<b>NO</b>	: Nitric Oxide
<b>PG</b>	: Prostaglandin
<b>PGF2alpha</b>	: Prostaglandin F2 alpha
<b>PROM</b>	: Premature Rupture Of Membrane
<b>PTH-RP</b>	: Parathyroid Hormone Related Peptide
<b>RPP</b>	: Rate Pressure Product
<b>TIMMPs</b>	: Tissue Inhibitors Matrix Metaloproteases
<b>TNFalpha</b>	: Tumor Necrosis Facor alpha
<b>TOL</b>	: Trial of Labor
<b>VD</b>	: Vaginal Delivery

## List of Tables

<b>Table No.</b>	<b>Title</b>	<b>Page No.</b>
<b>Table (1):</b>	Modified Bishop scoring system .....	34
<b>Table (2):</b>	Cesarean delivery rate (percent) for failed induction by Bishop score and parity, circa 1985 (prior to availability of prostaglandins).....	37
<b>Table (3):</b>	Examples of oxytocin infusion protocols .....	60
<b>Table (4):</b>	Basal demographic characteristics among the studied groups .....	100
<b>Table (5):</b>	Duration of latent phase of labor (hours) among the studied groups .....	101
<b>Table (6):</b>	Duration of active phase (hours) among the studied groups .....	102
<b>Table (7):</b>	Duration of second stage of labor (minutes) among the studied groups .....	103
<b>Table (8):</b>	Mode of delivery among the studied groups .....	104
<b>Table (9):</b>	Duration of third stage of labor (minutes) among the studied groups .....	106
<b>Table (10):</b>	Neonatal condition among the studied groups.....	107

## List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Figure (1):</b>	$\beta$ -adrenergic receptor stimulation by epinephrine molecule .....	67
<b>Figure (2):</b>	Patients' flow chart .....	99
<b>Figure (3):</b>	Duration of latent phase among the studied groups .....	101
<b>Figure (4):</b>	Duration of active phase of labor among the studied groups .....	102
<b>Figure (5):</b>	Duration of second stage of labor among the studied groups .....	103
<b>Figure (6):</b>	Mode of delivery among the studied groups .....	105
<b>Figure (7):</b>	Duration of third stage of labor among the studied groups .....	106

**Propranolol and Oxytocin Versus Oxytocin  
Alone for Induction of Labor:  
A Randomized Controlled Trial**

**Protocol of a Thesis**

Submitted for partial fulfillment of Master degree  
in *Obstetrics and Gynecology*

**By**

**Abd El-Rahman Mahmoud Abd El-Rahman**

*M.B,B.Ch Al-Azhar University - 2010*

*Resident of Obstetrics & Gynecology – Tahta General Hospital*

**Under Supervision of**

**Prof. Magdy Mohamed Mahmoud Abd El-Gawad**

*Professor of Obstetrics and Gynecology*

*Faculty of Medicine - Ain-Shams University*

**Dr. Reda Mokhtar Kamal**

*Lecturer of Obstetrics and Gynecology*

*Faculty of Medicine - Ain-Shams University*

**Faculty of Medicine**

**Ain Shams University**



2017

## **INTRODUCTION**

Labor is defined as the state of being in uterine contractions of adequate frequency, duration, and strength to cause effacement and dilataion of the cervix (*ACOG, 2003*). Induction of labor is defined as stimulation of uterine contractions before they occur spontaneously (*Martin et al., 2006*).

Prolonged labor can lead to maternal and neonatal complications, and these adverse labor outcomes increase in prolonged pregnancy in comparison with term gestational age (*Cheng et al., 2009*). The rates of cesarean section are increasing during the last decade in an international setting (*Roberts et al., 2015*). Previous studies suggested that induction of labor might be associated with increased rates of CS. High maternal and gestational age at delivery affect these rates both in nulliparous and multiparous women. Similarly, the presence of low Bishop score and a neonatal birth weight >3.5 kg increase the possibility of failure of induction (*Ramasamy and Thunga, 2011*). The contribution of trial of labor (TOL) on the cesarean section rates has become a matter of debate during the last decade. Recent meta-analyses, however, suggest it doesn't influence these rates (*Wood and Cooper, 2014*).

Oxytocin is the best known and most widely used agent to induce and augment uterine contractions (*Hinshaw et al., 2008*); but the Institute for Safe Medication has termed oxytocin as a *high-alert medication* due to the risk of high dose or wrong prescription. This institute



recommended many programs to minimize the maternal and neonatal risks of oxytocin administration (*Palomaki et al., 2006*).

Other agents are currently used for induction and augmentation of labor as prostaglandins are the most widely spread. Intravaginal misoprostol (PGE<sub>1</sub>) seems to be more efficient and less expensive than dinoprostone (PGE<sub>2</sub>) which is applied intracervically or intravaginally, although evidence in this field are contradictory (*Jha et al., 2015*). However, dinoprostone appears to be safer because it is accompanied by lower incidence of uterine hyperstimulation and tachysystole (*Liu et al., 2014*).

Taking into mind the potential side effects of misoprostol and the expensive value of dinoprostone, it would be prudent to investigate the efficacy of other agents in the field. In the last 20 years, scarce evidence have been reported regarding propranolol's efficacy and mode of action during the latent and active phases of labor. Propranolol is a sympatholytic non-selective beta-blocker. Twenty five years ago, *Peiker et al.* suggested that it causes contractions of uterine muscle stripes in pregnant rats and eventually to induction of labor. Since then, various molecular pathways which involve the adrenergic system have been implicated in the regulation of uterine contractility (*Rouget et al., 2005*).

Despite these evidence, however, the interest in propranolol use as a means to induce and/or enhance contractions is very limited.

Direkvand-Moghadam et al. studied the Comparison Effect of Oral Propranolol and Oxytocin Versus Oxytocin Only on Induction of Labour in Nulliparous Women and found that The mean duration for obtaining good contractions was significantly shorter in the Propranolol group than in the placebo group, on both the first and second day of induction ( $p < .05$ ). The mean duration of latent phase was shorter in the first in Propranolol group ( $p < .05$ ). In Propranolol plus Oxytocine group, frequency of cesarean deliveries significantly decreased than in the placebo plus Oxytocin group (21% versus 39.7%). No significant differences in neonate outcome, such as Apgar scores of minutes 1 and 5 and need of admissions to NICU, were found between the groups ( $p > .05$ ) (*Direkvand-Moghadam et al., 2013*).

Pergialiotis et al., were studied Propranolol and oxytocin versus oxytocin alone for induction and augmentation of labor and found that propranolol administration during the latent phase effectively reduces the cesarean section rates (OR 0.49, 95 % CI 0.27, 0.89). However, this beneficial effect is not observed during the active phase of labor. The 5 min neonatal Apgar scores are not influenced by its administration (MD -0.07, 95 % CI -0.017, 0.02). Respectively, the neonatal admissions to a NICU are similar to those of neonates exposed only to oxytocin (OR 0.96, 95 % CI 0.36, 2.53 (*Pergialiotis et al., 2016*).

## **AIM OF THE WORK**

The aim of this study is to evaluate the efficacy of propranolol supplementary agent to oxytocin in women undergoing induction of labor to decrease cesarean section rate.

### **Research hypothesis :**

In pregnant women undergoing induction of labor propranolol supplementary agent to oxytocin may decrease the rate of cesarean section.

### **Research question:**

In pregnant women undergoing induction of labor does propranolol supplementary agent to oxytocin decrease the rate of cesarean section?

### **Outcome measures :**

#### ***1-Primary outcome:***

Evaluation and measurement the efficacy of propranolol supplementary agent to oxytocin in women undergoing induction of labor to decrease cesarean section rate.

## ***2-Secondary outcome:***

Evaluation and measurement the efficacy of propranolol supplementary agent to oxytocin in women undergoing induction of labor on

- Duration of latent phase.
- Duration of active phase .
- Duration of second stage.
- Mode of delivery.
- Neonatal condition after labor as APGAR scores and NICU admission.

## **SUBJECTS AND METHODS**

**Study design:** Randomized controlled clinical trial.

**Settings:** Ain Shams Maternity University Hospital in the period between May 2017 and May 2018.

**Population:** The study will include 160 women planned for induction of labor.

**Sample size justification:** Sample size will be calculated using MedCalc<sup>®</sup> version 12.3.0, setting the power ( $\beta$ ) at 0.02 and the significance level ( $\alpha$ ) at 0.05. Data from previous reports (*Pergialiotis et al., 2016*) indicated that propranolol administration during the latent phase effectively reduces the cesarean section rates with OR 0.49 (95% CI: 0.27-0.89). Calculation according to these values produced a minimal sample size of 152 women to yield statistically significant results. Assuming a drop-out rate of 5%, a total sample size will approximately be 160 women, to be randomized into 2 groups.

## **RESEARCH METHODOLOGY**

- After approval of the ethical committee, all participants in the study will give a written, informed consent, after explaining the details of the study to them (appendix 1).

### **Inclusion Criteria:**

- Age between 20 years and 35 years.
- Gestational age 38 - 41 weeks (according to a reliable last menstrual period and ultrasound evaluation at first trimester).

- Singleton viable pregnancy.
- Cephalic vertex presentation.
- Intact membranes..
- Bishop score  $> 5$ .
- Reassuring fetal well-being status.
- Maternal BMI btween (18-30kg/m<sup>2</sup>).
- Primigravida,or Previous one or previous two vaginal delivery.

**Exclusion Criteria:**

- Age more than 35 years or less than 20 years.
- Multiple pregnancy.
- Multigravida more than two vaginal delivery.
- Non-cephalic presentation.
- Presence of uterine contractions.
- History of uterine surgery eg. Cesarean section, myomectomy.
- Polyhydramnios.
- Pre-labor rupture of membranes.
- Non-reassuring fetal well-being status
- Contraindications to  $\beta$ -adrenergic agents, such as systolic blood pressure less than 100 mmHg or pulse rate less than 60/min and more than 120/min
- History of any known cardiac disease
- Mother's pulmonary or metabolic disorders
- Fetal distress
- Intrauterine fetal death.
- Estimated weight of the fetus more than 4 kg by ultrasound of cephalic presentation.
- Maternal obesity BMI  $> 30$ kg/m<sup>2</sup>.
- Underwight patient BMI  $< 18$ kg/m<sup>2</sup>.

### **Randomization:**

Patients fulfilling the inclusion criteria will be randomized to two groups.

### **Study Group:**

This group will include 80 women undergoing induction of labor. In this group, patients will receive a tablet containing 20 mg propranolol orally two hours before beginning induction, in addition to intravenous oxytocin. The tablet will be repeated after 8 hours if no sufficient uterine contractions have been reached.

### **Control Group:**

This group will include 80 women undergoing induction of labor. In this group, patients will receive a placebo tablet orally before beginning induction, in addition to intravenous oxytocin. The tablet will be repeated after 8 hours if no sufficient uterine contractions have been reached.

### **Random allocation sequence generation**

A computer generated list via MedCalc<sup>®</sup> Software, version 13.2.2 will be used, assigning each participant number to either study groups (appendix 2).

### **Allocation Concealment**

Assignment will be done by sequentially numbered, otherwise identical, sealed envelopes (SNOSE), each containing a 2-inch by 2-inch paper with a written code designating the assigned group. These papers will be placed in a folded sheet of aluminum foil fitted inside the envelope. Effort will be taken to assure absence of any detectable differences in size or weight between intervention and control envelopes. Envelopes will be